<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<rss version="2.0">
<channel>
<title>Mylan Media Room</title>
<link>http://media.mylan.com/</link>
<description></description>
<item>
<title>Mylan's President of Europe, Middle East and Africa Elected President of European Generic Medicines Association</title>
<link>http://media.mylan.com/index.php?s=43&amp;item=471</link>
<description></description>
<pubDate>Wed, 18 Nov 2009 15:01:00 -0500</pubDate>
<guid>http://media.mylan.com/index.php?s=43&amp;item=471</guid>
</item>
<item>
<title>Mylan's Spanish Business Named Best Generic Pharmaceuticals Company in Spain by Elsevier</title>
<link>http://media.mylan.com/index.php?s=43&amp;item=470</link>
<description></description>
<pubDate>Thu, 12 Nov 2009 08:00:00 -0500</pubDate>
<guid>http://media.mylan.com/index.php?s=43&amp;item=470</guid>
</item>
<item>
<title>Mylan Receives FDA Approval for Generic Version of Prevacid® Through its Subsidiary Matrix Laboratories</title>
<link>http://media.mylan.com/index.php?s=43&amp;item=469</link>
<description></description>
<pubDate>Tue, 10 Nov 2009 15:24:00 -0500</pubDate>
<guid>http://media.mylan.com/index.php?s=43&amp;item=469</guid>
</item>
<item>
<title>Mylan Reports Third Quarter Adjusted Diluted EPS of $0.32</title>
<link>http://media.mylan.com/index.php?s=43&amp;item=468</link>
<description>Mylan Raises 2009 Adjusted Diluted EPS Guidance Range to $1.24 - $1.28</description>
<pubDate>Thu, 29 Oct 2009 06:30:00 -0400</pubDate>
<guid>http://media.mylan.com/index.php?s=43&amp;item=468</guid>
</item>
<item>
<title>Dey Launches and Unveils Next-Generation, Needle-Protected EpiPen(R) (Epinephrine) Auto-Injector with Enhanced Patient-Friendly Features</title>
<link>http://media.mylan.com/index.php?s=43&amp;item=466</link>
<description></description>
<pubDate>Mon, 26 Oct 2009 07:30:00 -0400</pubDate>
<guid>http://media.mylan.com/index.php?s=43&amp;item=466</guid>
</item>
</channel>
</rss>
